[Therapeutic intensification and autotransplantation of hematopoietic stem cells in metastatic breast cancers].
The first studies on intensive chemotherapy for metastatic breast cancer conducted in the 80s were disappointing. Despite good response rates, the duration of remission was short and long-term survivals exceptional. Nevertheless, these phase I and II trials helped to develop a better understanding of the potential indications of this new therapeutic approach and apprehend its technical aspects. Over the last 5 years, considerable progress has been made in grafting techniques and hematopoietic support greatly improving the safety of the method. Notwithstanding the financial considerations involved, it must be noted that the efficacy autologous stem cell support, in terms of recurrence-free overall survival, has not yet been demonstrated although the (controversial) results of two randomized controlled trials have recently been published. In France, the PEGASE programs for the study of autologous stem cell support in breast cancer have been developed in an attempt to elucidate the question.
Lotz
J P
JP
Service d'Oncologie médicale, Hôpital Tenon, Paris.
Pène
F
F
Bouleuc
C
C
André
T
T
Macovei
C
C
Laadem
A
A
Debourdeau
P
P
Gumus
Y
Y
Merad
Z
Z
Avenin
D
D
Esteso
A
A
Bellaiche
A
A
Izrael
V
V
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009362:Neoplasm Metastasis
D000970:Antineoplastic Agents
Intensification thérapeutique et autogreffe de cellules souches hématopoïétiques dans les cancers du sein métastatiques.